Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)

This publication has 15 references indexed in Scilit:

• Renal toxicity of the neuron-blocking and mitochondriotropic agent m -iodobenzylguanidine
  Cancer Chemotherapy and Pharmacology, 1998
• Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
  Proceedings of the National Academy of Sciences, 1997
• Reduction of intratumoral pH by the mitochondrial inhibitor m-iodobenzylguanidine and moderate hyperglycemia.
  1994
• Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry
  European Journal of Nuclear Medicine and Molecular Imaging, 1994
• Uptake of the neuron‐blocking agent meta‐iodobenzylguanidine and serotonin by human platelets and neuro‐adrenergic tumour cells
  International Journal of Cancer, 1993
• Pharmacokinetics and intracellular distribution of the tumor‐targeted radiopharmaceutical m‐iodo‐benzylguanidine in SK‐N‐SH neuroblastoma and PC‐12 pheochromocytoma cells
  International Journal of Cancer, 1991
• Impaired mitochondrial respiration and stimulated glycolysis by m‐iodobenzylguanidine (mibg)
  International Journal of Cancer, 1990
• Meta-iodobenzylguanidine (MIBG), a novel high-affinity substrate for cholera toxin that interferes with cellular mono(ADP-ribosylation)
  Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1990
• Cytotoxic and antitumor effects of the norepinephrine analogue meta-iodo-benzylguanidine (MIBG)
  Cancer Chemotherapy and Pharmacology, 1988
• The role of I-131-MIBG in the diagnosis and therapy of carcinoids
  European Journal of Nuclear Medicine and Molecular Imaging, 1987